Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.

[1]  E. Kékes.  Captopril in heart failure. , 1988, Acta physiologica Hungarica.

[2]  K. Dickstein,et al.  Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. , 1986, American heart journal.

[3]  L. Woie,et al.  Increase in plasma vasoactive intestinal polypeptide (VIP) in muscular exercise in humans. , 1986, General pharmacology.

[4]  K. Kawamura,et al.  Effects of Converting‐Enzyme Inhibition on Cardiorenal Hemodynamics in Patients with Chronic Congestive Heart Failure , 1985, Journal of cardiovascular pharmacology.

[5]  M. Packer,et al.  Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. , 1985, Circulation.

[6]  B. W. East,et al.  Captopril in heart failure. A double blind controlled trial. , 1984, British heart journal.

[7]  K. Helle,et al.  VIP inhibition of vascular smooth muscle: complementary to beta 2-adrenoceptor mediated relaxation in the isolated rat portal vein. , 1984, Acta physiologica Scandinavica.

[8]  I. Tikkanen,et al.  Enalapril and Lisinopril in Renovascular Hypertension Antihypertensne and Hormonal Effects of Two New Angio-Tensin-Converting-Enzyme (ACE) Inhibitors. , 1984, Scandinavian journal of urology and nephrology.

[9]  R. Zusman,et al.  Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. , 1984, Kidney international.

[10]  R. Davies,et al.  An overview of the clinical pharmacology of enalapril. , 1984, British journal of clinical pharmacology.

[11]  C. Zoccali,et al.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. , 1984, British journal of clinical pharmacology.

[12]  B. Kaada,et al.  In search of mediators of skin vasodilation induced by transcutaneous nerve stimulation: III. Increase in plasma VIP in normal subjects and in Raynaud's disease. , 1984, General pharmacology.

[13]  B. Kaada,et al.  Failure to influence the VIP level in the cerebrospinal fluid by transcutaneous nerve stimulation in humans. , 1984, General pharmacology.

[14]  J. Cohn,et al.  Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[15]  D. O'Connor,et al.  Autonomic and baroreflex function after captopril in hypertension. , 1983, American heart journal.

[16]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[17]  A. Vander,et al.  Reflex‐Hemodynamic Adjustments and Baroreflex Sensitivity During Converting Enzyme Inhibition with MK‐421 in Normal Humans , 1983, Hypertension.

[18]  R. Zusman.  Regulation of Prostaglandin Biosynthesis in Cultured Renal Medullary Interstitial Cells , 1983 .

[19]  J. Cohn,et al.  Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure. , 1982, American heart journal.

[20]  J. Biollaz,et al.  Enalapril maleate and a lysine analogue (MK-521): disposition in man. , 1982, British journal of clinical pharmacology.

[21]  J. Biollaz,et al.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. , 1982, British journal of clinical pharmacology.

[22]  P. Weber,et al.  Acute haemodynamic and hormonal effects of captopril are diminished by indomethacin. , 1982, Clinical science.

[23]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[24]  C. Johnston,et al.  Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. , 1982, The American journal of cardiology.

[25]  M. Weinberger.  Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients. , 1982, The American journal of cardiology.

[26]  G. Williams,et al.  Angiotensin-converting enzyme inhibition and prostaglandins. , 1982, The American journal of cardiology.

[27]  K. Silberbauer,et al.  Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. , 1982, British journal of clinical pharmacology.

[28]  R. Mathison,et al.  Adrenergic and peptidergic (substance P and vasoactive intestinal polypeptide) innervation of the rat portal vein. , 1982, Blood vessels.

[29]  R. Horton,et al.  Evidence for a dual action of converting enzyme inhibitor on blood pressure in normal man. , 1981, Prostaglandins.

[30]  T. Ogihara,et al.  Hormonal responses to long‐term converting enzyme inhibition in hypertensive patients , 1981, Clinical pharmacology and therapeutics.

[31]  J. Halperin,et al.  Acute Regional Circulatory and Renal Hemodynamic Effects of Converting‐enzyme Inhibition in Patients with Congestive Heart Failure , 1981, Circulation.

[32]  S. Podolsky,et al.  Contribution of Prostaglandins to the Antihypertensive Action of Captopril in Essential Hypertension , 1981, Hypertension.

[33]  E. Espiner,et al.  HAEMODYNAMIC, HORMONAL, AND ELECTROLYTE RESPONSES TO CAPTOPRIL IN RESISTANT HEART FAILURE , 1981, The Lancet.

[34]  Lundberg Jm.  Evidence for coexistence of vasoactive intestinal polypeptide (VIP) and acetylcholine in neurons of cat exocrine glands. Morphological, biochemical and functional studies. , 1981 .

[35]  S. Rattan,et al.  VIP as a possible neurotransmitter of non-cholinergic non-adrenergic inhibitory neurones , 1980, Nature.

[36]  A. Provoost.  The effect of prostaglandin synthesis inhibition of the acute blood pressure reduction by captopril in pentobarbital-anaesthetized rats. , 1980, European journal of pharmacology.

[37]  N. Hollenberg,et al.  Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. , 1980, The Journal of clinical investigation.

[38]  H. Nishimura,et al.  The renin-angiotensin-aldosterone system and catecholamines in chronic congestive heart failure. Effect of angiotensin I converting enzyme inhibitor SQ 14225 (Captopril). , 1980, Japanese circulation journal.

[39]  R. Türker,et al.  Potentiation by angiotensin converting enzyme inhibitor, SQ, 14225, of the analgesic effect of morphine in mice. , 1979, European Journal of Pharmacology.

[40]  H. Gavras,et al.  IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRIL , 1979, The Lancet.

[41]  M. Benuck,et al.  Co-identity of brain angiotensin converting enzyme with a membrane bound dipeptidyl carboxypeptidase inactivating Met - enkephalin. , 1979, Biochemical and biophysical research communications.

[42]  N. Hollenberg,et al.  Converting Enzyme Inhibition in Essential Hypertension: The Hypotensive Response Does Not Reflect Only Reduced Angiotensin II Formation , 1979, Hypertension.

[43]  R. Perdrisot,et al.  Is 'enkephalinase' identical with 'angiotensin-converting enzymes'? , 1979, European journal of pharmacology.

[44]  S. Bloom,et al.  Measurement of fasting and postprandial plasma VIP in man. , 1978, Gut.

[45]  U. Haglund,et al.  Nervous release of vasoactive intestinal polypeptide in the gastrointestinal tract of cats: possible physiological implications. , 1978, The Journal of physiology.

[46]  J. Holst,et al.  Influence of the autonomic nervous system on the release of vasoactive intestinal polypeptide from the porcine gastrointestinal tract. , 1978, The Journal of physiology.

[47]  E. G. Erdös,et al.  Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase. , 1978, Biochemical pharmacology.

[48]  Zimmerman Bg.  Actions of angiotensin on adrenergic nerve endings. , 1978 .

[49]  K. Malik.  Prostaglandins--modulation of adrenergic nervous system. , 1978, Federation proceedings.

[50]  T. Waldron,et al.  Inhibition of Angiotensin-Converting Enzyme by SQ 14,225 in Anesthetized Dogs: Hernodynamic and Renal Vascular Effects , 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[51]  J. Fahrenkrug,et al.  Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma. , 1978, Advances in experimental medicine and biology.

[52]  R. Zusman,et al.  Prostaglandin E2 biosynthesis by rabbit renomedullary interstitial cells in tissue culture. Mechanism of stimulation by angiotensin II, bradykinin, and arginine vasopressin. , 1977, The Journal of biological chemistry.

[53]  I. Kopin,et al.  Age-adjusted plasma norepinephrine levels are similar in normotensive and hypertensive subjects. , 1977, The New England journal of medicine.

[54]  R. Soffer.  Angiotensin-converting enzyme and the regulation of vasoactive peptides. , 1976, Annual review of biochemistry.

[55]  N. Christensen,et al.  Catecholamines in plasma and urine in patients with essential hypertension determined by double-isotope derivative techniques. , 2009, Acta medica Scandinavica.

[56]  K. Malik,et al.  Release of a Prostaglandin E‐Like Substance from Canine Kidney by Bradykinin: COMPARISON WITH ELEDOISIN , 1972, Circulation research.

[57]  V. Dequattro,et al.  Raised plasma-catecholamines in some patients with primary hypertension. , 1972, Lancet.

[58]  R. Roth,et al.  Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation , 1971, British journal of pharmacology.

[59]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[60]  V. Mutt,et al.  Potent Peripheral and Splanchnic Vasodilator Peptide from Normal Gut , 1970, Nature.

[61]  Y. S. Bakhle,et al.  Conversion of Angiotensin I to Angiotensin II by Cell-free Extracts of Dog Lung , 1968, Nature.

[62]  J. Vane,et al.  Fate of Angiotensin I in the Circulation , 1968, Nature.

[63]  J. Vane,et al.  Conversion of Angiotensin I to Angiotensin II , 1967, Nature.

[64]  W. Bailey.  Further Investigations into the Function of the “Mirror” in Tettigonioidea (Orthoptera) , 1967, Nature.

[65]  J. Vane,et al.  The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. , 1967, British journal of pharmacology and chemotherapy.

[66]  P. Khairallah,et al.  Inhibition of noradrenaline uptake by angiotensin , 1967, The Journal of pharmacy and pharmacology.

[67]  O. M. Helmer.  Differentiation between two forms of angiotonin by means of spirally cut strips of rabbit aorta. , 1957, The American journal of physiology.

[68]  S. Siegel,et al.  Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.